166 related articles for article (PubMed ID: 2378787)
1. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
Schellens JH; van der Wart JH; Breimer DD
Br J Clin Pharmacol; 1990 Jun; 29(6):665-71. PubMed ID: 2378787
[TBL] [Abstract][Full Text] [Related]
2. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.
Meier UT; Dayer P; Malè PJ; Kronbach T; Meyer UA
Clin Pharmacol Ther; 1985 Nov; 38(5):488-94. PubMed ID: 4053486
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation.
Küpfer A; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):414-8. PubMed ID: 4042524
[TBL] [Abstract][Full Text] [Related]
4. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
5. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
6. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
Küpfer A; Preisig R
Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
[TBL] [Abstract][Full Text] [Related]
8. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
9. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
Inaba T; Jurima M; Nakano M; Kalow W
Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2.
Yasumori T; Murayama N; Yamazoe Y; Kato R
Clin Pharmacol Ther; 1990 Mar; 47(3):313-22. PubMed ID: 2311333
[TBL] [Abstract][Full Text] [Related]
11. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
Skjelbo E; Gram LF; Brøsen K
Br J Clin Pharmacol; 1993 Mar; 35(3):331-4. PubMed ID: 8471415
[TBL] [Abstract][Full Text] [Related]
12. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
[TBL] [Abstract][Full Text] [Related]
13. Family studies of mephenytoin hydroxylation deficiency.
Inaba T; Jurima M; Kalow W
Am J Hum Genet; 1986 May; 38(5):768-72. PubMed ID: 3717162
[TBL] [Abstract][Full Text] [Related]
14. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation.
Knodell RG; Dubey RK; Wilkinson GR; Guengerich FP
J Pharmacol Exp Ther; 1988 Jun; 245(3):845-9. PubMed ID: 3385644
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.
Wedlund PJ; Aslanian WS; Jacqz E; McAllister CB; Branch RA; Wilkinson GR
J Pharmacol Exp Ther; 1985 Sep; 234(3):662-9. PubMed ID: 4032286
[TBL] [Abstract][Full Text] [Related]
16. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
17. Stereoselectivity of the arene epoxide pathway of mephenytoin hydroxylation in man.
Küpfer A; Lawson J; Branch RA
Epilepsia; 1984 Feb; 25(1):1-7. PubMed ID: 6420144
[TBL] [Abstract][Full Text] [Related]
18. Relationship between mephenytoin, phenytoin and tolbutamide hydroxylations in healthy African subjects.
Horsmans Y; Kanyinda JM; Desager JP
Pharmacol Toxicol; 1996 Feb; 78(2):86-8. PubMed ID: 8822040
[TBL] [Abstract][Full Text] [Related]
19. Mephenytoin hydroxylation deficiency: kinetics after repeated doses.
Küpfer A; Desmond P; Patwardhan R; Schenker S; Branch RA
Clin Pharmacol Ther; 1984 Jan; 35(1):33-9. PubMed ID: 6690169
[TBL] [Abstract][Full Text] [Related]
20. A major pathway of mephenytoin metabolism in man. Aromatic hydroxylation to p-hydroxymephenytoin.
Küpfer A; Brilis GM; Watson JT; Harris TM
Drug Metab Dispos; 1980; 8(1):1-4. PubMed ID: 6102023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
